Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone
| Autor: | Asbjørn Mohr Drewes, Grzegorz J. Pacyk, Jens Peter Kroustrup, Kenneth T. Kongstad, David J. R. Foster, Ahmad Y. Abuhelwa, Lona L. Christrup, Louise Ladebo, Anne Estrup Olesen |
|---|---|
| Přispěvatelé: | Ladebo, Louise, Abuhelwa, Ahmad Y., Foster, David JR, Kroustrup, Jens P, Pacyk, Grzegorz J, Kongstad, Kenneth T, Drewes, Asbjørn M, Christrup, Lona L, Olesen, Anne E |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Roux-en-Y gastric bypass Gastric bypass Gastric Bypass Administration Oral Toxicology oxycodone Gastroenterology Random Allocation Internal medicine medicine Humans Aged Pharmacology Aged 80 and over Cross-Over Studies business.industry Pharmacokinetic pharmacodynamic General Medicine oral solution Middle Aged Roux-en-Y anastomosis Bioavailability Analgesics Opioid Controlled-Release Formulations Pharmacodynamics Delayed-Action Preparations Female pharmacokinetic-pharmacodynamic modelling business Oxycodone oral controlled-release formulation Blood sampling medicine.drug |
| Zdroj: | Ladebo, L, Abuhelwa, A Y, Foster, D J R, Kroustrup, J P, Pacyk, G J, Kongstad, K T, Drewes, A M, Christrup, L L & Olesen, A E 2021, ' Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone ', Basic & Clinical Pharmacology & Toxicology, vol. 129, no. 3, pp. 232-245 . https://doi.org/10.1111/bcpt.13634 |
| DOI: | 10.1111/bcpt.13634 |
| Popis: | The physiological changes following Roux-en-Y gastric bypass (RYGB) surgery may impact drug release from mechanistically different controlled-release tablets, making generic substitution inappropriate. This study aimed to characterise the pharmacokinetic-pharmacodynamic relationships of oxycodone from a lipid-based and water-swellable controlled-release tablet in RYGB patients. Twenty RYGB patients received 10-mg oral solution oxycodone or 20-mg controlled-release (water-swellable or lipid-based) oxycodone in a three-way, randomised, semiblinded and cross-over study. Blood sampling and pupillary recordings were conducted over a 24-h period. A previously established pharmacokinetic-pharmacodynamic model of these three formulations in healthy volunteers was used in the analysis as a reference model. No differences in absorption kinetics were seen between controlled-release formulations in patients. However, the absorption lag time was 11.5 min in patients vs 14 min in healthy volunteers for controlled-release tablets (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|